Cagrilintide
Tested in peopleIt has been tested in people, but it is not an approved medicine. The studies are usually small.
Also called AM833 / NNC0174-0833
Copies a hunger hormone called amylin. Being tested alongside semaglutide as a combination called CagriSema.
Can a doctor prescribe this?
No. Pharmacies are not on record as being allowed to make this into a medicine.
The FDA has not approved this as a medicine.
Investigational. Not approved and not legal to compound.
Official status: Not on the 503A bulks list. Checked 2026-08-04.
Lab suppliers we list: 8
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
In human trials
See source wording
under the skin · weekly
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightPHASE3 · NCT06131437
“CagriSema 2.4 mg/2.4 mg.”
See source wording
under the skin · weekly · for 8 weeks
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy ParticipantsPHASE1 · NCT05804162
“Participants will receive 0.6 mg subcutaneous injections of cagrilintide once weekly and the dose will be then escalated once in 2 weeks for 8 weeks until the target maintenance dose of 4.5 mg is reached followed by a 38-day post-treatment period..”
2.4 mg
under the skin · once a week · for 32 weeks
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesPHASE2 · NCT04982575
“Semaglutide 2.4 mg.”
See source wording
weekly · for 14 weeks
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or ObesityPHASE1 · NCT04940078
“Once weekly doses of cagrilintide gradually increased to 1.7 mg over 14 weeks and 2.4 mg s.c.”
See source wording
under the skin · weekly · for 52 weeks
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightPHASE3 · NCT05813925
“Participants will receive 2.4 mg cagrilintide s.c.”
2.4 mg
under the skin · weekly · for 44 weeks
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose WeightPHASE3 · NCT05996848
“Participants will receive 2.4 mg cagrilintide subcutaneously..”
In animal studies
See source wording
mice · under the skin · for 23 weeks
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.EBioMedicine · 2025
“Male wild-type (WT) and KO littermate mice were fed high-fat diet for 23 weeks prior to the 3-week treatment period with vehicle, 150 nmol/kg sCT or 3 nmol/kg cagrilintide (subcutaneously, SID).”
12 mg
rats · weekly
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.Molecular metabolism · 2025
“A phase 1, randomized, placebo-controlled, participant/investigator-blinded trial evaluated the safety and tolerability of single-ascending eloralintide doses (0.04-12 mg) in healthy participants (NCT05295940).”
- Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
Study in people
The lancet. Diabetes & endocrinology · 2026
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Study in people
Lancet (London, England) · 2026
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
Study in people
The lancet. Diabetes & endocrinology · 2026
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
Study in people
The lancet. Diabetes & endocrinology · 2026
- Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
Study in people
The lancet. Gastroenterology & hepatology · 2026
- A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.
Animal study, rats or mice
Nature metabolism · 2026
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
Animal study, rats or mice
Peptides · 2026
- Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.
Animal study, rats or mice
Nature metabolism · 2026
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
Animal study, rats or mice
EBioMedicine · 2025
- In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive doping research.
Lab dish study
Journal of pharmaceutical and biomedical analysis · 2026
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.
Lab dish study
Molecular metabolism · 2025
- Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide.
Lab dish study
Life sciences · 2025
- Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.
Clinical pharmacokinetics · 2026
- Cagrilintide-semaglutide: a new option for patients with type 2 diabetes.
The lancet. Diabetes & endocrinology · 2026
- Cellular loci for cagrilintide action identified.
Nature metabolism · 2026
- Mitochondrial Adaptations in Skeletal Muscle Following Incretin-Based Therapies: In Vitro.
Journal of cachexia, sarcopenia and muscle · 2026
- Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Diabetes, obesity & metabolism · 2026
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
Hypertension (Dallas, Tex. : 1979) · 2026
- Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.
Journal of diabetes science and technology · 2026
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.
Acta pharmacologica Sinica · 2026
- Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
Journal not recorded · 2026
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
The New England journal of medicine · 2025
- In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk.
Annals of internal medicine · 2025
- Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.
Review of earlier work
Journal of obesity & metabolic syndrome · 2026
- Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
Review of earlier work
Endocrinology, diabetes & metabolism · 2026
- Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis.
Review of earlier work
Journal of diabetes and metabolic disorders · 2026
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
Review of earlier work
Diabetes, obesity & metabolism · 2026
- Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.
Review of earlier work
Diabetes, obesity & metabolism · 2026
- Beyond weight loss: multisystem benefits of obesity medications.
Review of earlier work
The lancet. Diabetes & endocrinology · 2026
- Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Review of earlier work
Annals of internal medicine · 2026
- Cagrilintide–Semaglutide Combination Therapy Versus Monotherapy or Placebo: A Systematic Review and Meta-Analysis
Review of earlier work
Journal not recorded · 2025
- Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.
Review of earlier work
Metabolism open · 2025
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.
Review of earlier work
Indian journal of endocrinology and metabolism · 2024
- Amylin as a Future Obesity Treatment.
Review of earlier work
Journal of obesity & metabolic syndrome · 2021